A Crossover Safety Study of Ferumoxytol Versus Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00255450
Recruitment Status : Completed
First Posted : November 21, 2005
Last Update Posted : November 11, 2008
Information provided by:
AMAG Pharmaceuticals, Inc.

Brief Summary:
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.

Condition or disease Intervention/treatment Phase
Anemia Drug: ferumoxytol or placebo Phase 3

Detailed Description:
This is a double-blind, placebo controlled, crossover design study of the safety of ferumoxytol compared to placebo. Patients are randomized to receive either one 510 mg dose of ferumoxytol or the equivalent volume of normal saline followed by the other test article given one week later.

Study Type : Interventional  (Clinical Trial)
Enrollment : 750 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo
Study Start Date : January 2005
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia
Drug Information available for: Ferumoxytol
U.S. FDA Resources

Primary Outcome Measures :
  1. Safety evaluated by physical examinations, vital signs, laboratory tests and patient monitoring and evaluation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients > 18 years.
  • Have chronic kidney disease per K/DOQI guidelines.
  • Baseline hemoglobin of > 9.0 and < 12.5 g/dl

Exclusion Criteria:

  • Women who are pregnant or lactating.
  • Received another investigational drug or device within 30 days.
  • Recent parenteral or oral iron therapy.
  • Patients that have other causes of anemia.
  • Major surgery within 30 days or anticipated or planned surgery during the study.
  • Patients with active infections.
  • Recent blood transfusions.
  • Patients with known allergies to iron products.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00255450

  Show 41 Study Locations
Sponsors and Collaborators
AMAG Pharmaceuticals, Inc.

Additional Information:
Publications of Results:
Other Publications: Identifier: NCT00255450     History of Changes
Other Study ID Numbers: 62745-8
First Posted: November 21, 2005    Key Record Dates
Last Update Posted: November 11, 2008
Last Verified: October 2007

Keywords provided by AMAG Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Ferrosoferric Oxide
Parenteral Nutrition Solutions
Pharmaceutical Solutions